Endoplasmic Reticulum Stress Plays a Key Role in the Pathogenesis of Diabetic Peripheral Neuropathy

Sergey Lupachyk, Pierre Watcho, Roman Stavniichuk, Hanna Shevalye, and Irina G. Obrosova†

Endoplasmic reticulum stress resulting from abnormal folding of newly synthesized proteins impairs metabolism, transcriptional regulation, and gene expression, and it is a key mechanism of cell injury. Endoplasmic reticulum stress plays an important role in cardiovascular and neurodegenerative diseases, cancer, and diabetes. We evaluated the role for this phenomenon in diabetic peripheral neuropathy. Endoplasmic reticulum stress manifest in upregulation of multiple components of unfolded protein response was identified in neural tissues (sciatic nerve, spinal cord) of streptozotocin diabetic rats and mice. A chemical chaperone, trimethylamine oxide, administered for 12 weeks after induction of diabetes (110 mg·kg$^{-1}$·d$^{-1}$), a prevention paradigm attenuated endoplasmic reticulum stress, peripheral nerve dysfunction, intraepidermal nerve fiber loss, and sciatic nerve and spinal cord oxidative-nitrative stress in streptozotocin diabetic rats. Similar effects on diabetes-induced endoplasmic reticulum stress and peripheral nerve dysfunction were observed with a structurally unrelated chemical chaperone, 4-phenylbutyric acid (100 mg·kg$^{-1}$·d$^{-1}$, intraperitoneal). CCAAT/enhancer-binding protein homologous protein (CHOP)$^{-/-}$ mice made diabetic with streptozotocin displayed less severe sciatic nerve oxidative-nitrative stress and peripheral neuropathy than the wild-type (C57Bl6/J) mice. Neither chemical chaperones nor CHOP gene deficiency reduced diabetic hyperglycemia. Our findings reveal an important role of endoplasmic reticulum stress in the development of diabetic peripheral neuropathy and identify a potential new therapeutic target.

Diabetic peripheral neuropathy (DPN) affects at least 50% of patients with both type 1 and type 2 diabetes and is a leading cause of foot amputation (1,2). Clinical indications of DPN include increased vibration and thermal perception thresholds that progress to sensory loss, occurring in conjunction with degeneration of all fiber types in the peripheral nerve. A proportion of patients with DPN also describe abnormal sensations such as paresthesias, allodynia, hyperalgesia, and spontaneous pain (3). The pathogenetic mechanisms of DPN include, but are not limited to, increased aldose reductase activity (4), advanced glycation/glycoxidation (5), oxidative-nitrative stress (6–12), activation of protein kinase C (13), poly(ADP-ribose) polymerase (14,15), cyclooxygenase-2 (16), 12/15-lipoxygenase (17), and impaired neurotrophic support (18). Unfortunately, all drug candidates for DPN studied so far, including aldose reductase and protein kinase C inhibitors, acetyl carnitine, nerve growth factor, and the antioxidant α-lipoic acid, showed modest efficacy in clinical trials or adverse side effects. Identification of principally novel therapeutic targets for DPN therefore is highly warranted.

The endoplasmic reticulum (ER) plays a pivotal role in the folding and processing of newly synthesized proteins. Damage to ER and resultant ER stress lead to aberrant transcriptional regulation and gene expression, ion channel function, metabolism, and signaling (19–21). To counteract ER stress, the ER mounts the unfolded protein response (UPR). Three canonical arms of UPR, such as: PKR-like eukaryotic initiation factor 2A kinase (PERK), which phosphorylates eukaryotic initiation factor 2α (eIF2α) to suppress general protein translation; mammalian-targeting enzyme-1 (IRE1) involved in recruitment of several signaling molecules, splicing, and production of an active transcription factor called X box-binding protein 1, ER chaperones such as glucose-regulated protein BiP/GRP78 (BiP) and glucose-regulated protein 94 (GRP94), as well as CCAAT/enhancer-binding protein homologous protein (CHOP) and other components of the ER-associated degradation process; and activating transcription factor-6 (ATF-6), which translocates to the Golgi apparatus and produces an active transcription factor ATF-6N stimulating expression of chaperones and X box-binding protein 1, act together to reduce general protein synthesis, to facilitate protein degradation, and to increase folding capacity to resolve ER stress (19–21). However, the excessive and long-term upregulation of UPR and, in particular, X box-binding protein 1, CHOP, and ATF-4 leads to cell injury and death (19–21).

ER stress plays a key role in cardiovascular (21–23) and neurodegenerative (24) diseases, cancer (25), obesity, and diabetes mellitus (19,20,26–28). Recent experimental studies implicate ER stress in the development of diabetes complications, such as nephropathy (29), early retinopathy (30), and cognitive decline (31). We evaluated the contribution of ER stress to functional and morphological changes associated with experimental DPN.

RESEARCH DESIGN AND METHODS

Reagents. Unless otherwise stated, all chemicals were of reagent-grade quality and were purchased from Sigma-Aldrich Chemical (St. Louis, MO). For immunohistochemistry, rabbit polyclonal antiprotein gene product 9.5 (PGP 9.5) antiseraum for assessment of intraepidermal nerve fiber density (INFD) (UltraClone, Isle of Wight, UK), Alexa Fluor 488 goat anti-rabbit highly cross-adsorbed IgG (H+L, Invitrogen, Eugene, OR), SuperBlock blocking buffer (Thermo Scientific, Rockford, IL), and the optimum cutting temperature compound (Sakura Finetek USA, Torrance, CA) were used. VECTASHIELD Mounting Medium was obtained from Vector Laboratories (Burlingame, CA). Other reagents for immunohistochemistry have been purchased from Dako Laboratories (Santa Barbara, CA). For Western blot analysis, rabbit polyclonal anti-GFP78/BiP and anti-GRP94 antibodies and mouse monoclonal horseradish peroxidase-conjugated antibactin antibody were obtained from Abcam (Cambridge, MA), rabbit polyclonal anti-human IRE1p and phosphorylated (Ser724) anti-human IRE1p antibodies...
were obtained from USBiological (Swampscott, MA), rabbit polyclonal anti-phospho-PERK and anti-PERK antibodies and mouse monoclonal anti-ER oxidase 1 (ERO1)-Lx antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), rabbit polyclonal anti-phospho-eIF2α (ser51) and anti-eIF2α antibodies, and mouse monoclonal anti-CHOP antibody, and rabbit IgG horseradish peroxidase-linked antibodies were obtained from Cell Signaling (Danvers, MA), and mouse monoclonal (clone IAE) anti-trypotrypsine (NT) antibody was obtained from Millipore (Billerica, MA).

Animals. We used two models of DPN, i.e., male Wistar rats and male C57Bl6J mice that have development of robust peripheral nerve dysfunction and intraepidermal nerve fiber density when made diabetic with streptozotocin (STZ) (4–9,12–15,17,18). In the rat model, we conducted pharmacological studies with trimethoxylate (TMAO) and 4-phenylbutyric acid (PBA), two structurally unrelated chemical chaperones. Restoring ER function by chemical chaperones, i.e., compounds that counteract ER stress completely by promoting normal protein folding, is an emerging therapeutic approach for metabolic diseases recently used in a first clinical trial (27). Identification of the important role for ER stress completely in peripheral nerve dysfunction and degeneration in the chemical chaperone experiments consequently led us to the studies of individual components of ER stress and UPR using the specific inhibitors and transgenic mouse models. Herein, we report our findings in CHOP-deficient mice. The experiments were performed in accordance with regulations specified by the Guide for the Care and Handling of Laboratory Animals published by the National Institutes of Health, United States National Institutes of Health (Bethesda, VA, Italy). Pressure increasing at a linear rate of 10 g with the cut-off of 250 g to avoid tissue injury was applied to the dorsal surface of the paw (rats) or base of the tail (mice). The applied tail pressure that evoked biting or licking behavior was applied at least 20 s with a pressure of 1.3°C per second, cut-off time of 35 s for rats and 30 s for mice) was recorded. Floor temperature was set at 32–33°C (manufacturer’s set-up). Individual measurements were repeated four to five times and the mean value was calculated.

Tail pressure thresholds were registered with a paw/tail pressure analgesia meter for the Randall–Selitto test (37215, Analgesy-Meter; UGO-Basile, Comerio VA, Italy). Pressure increasing at a linear rate of 10 g with the cut-off of 250 g to avoid tissue injury was applied to the dorsal surface of the paw (rats) or base of the tail (mice). The applied tail pressure that evoked biting or licking behavior was applied at least 20 s with a pressure of 1.3°C per second, cut-off time of 35 s for rats and 30 s for mice) was recorded. Floor temperature was set at 32–33°C (manufacturer’s set-up). Individual measurements were repeated four to five times and the mean value was calculated.

Tactile responses were evaluated by quantifying the withdrawal threshold of the hindpaw in response to stimulation with flexible von Frey filaments as described in detail previously (14,17).

Intraepidermal nerve fiber density. Three longitudinal 50-μm-thick footpad sections from each rat were cut on Leica CM1550 cryostat (Leica Microsystems, Nussloch, Germany). Nonspecific binding was blocked by 3% goat serum containing 0.5% porcine gelatin and 0.5% Triton X-100 in SuperBlock blocking buffer at room temperature, for 2 h. The sections were incubated overnight with PGP 9.5 antisem in 1:400 dilution at 4°C, after which secondary Alexa Fluor 488 IgG (H+L) in 1:1,000 was applied at room temperature overnight with PGP 9.5 antiserum in 1:400 dilution at 4°C, after which sections were washed in 100 mmol/L Tris-buffered saline (PBS) and the sections were air-dried and mounted on gelatinized glass slides. Sections were preincubated with 5% (wt/vol) BSA (CHOP, GRP94, nitrated proteins), or 5% (wt/vol) nonfat dry milk (total PERK and eIF2α, phosphorylated and total IRE1α, CHOP, GRP78, GRP94, and nitrated proteins) sodium dodecyl sulfate (SDS) polyacrylamide gels, and the electrophoresis was conducted for 2 h. After blocking free binding sites as described, primary antibodies against phosphorylated PERK, eIF2α, and IRE1α, and ERO1α, BIP/GRP78, GRP94, and nitrated proteins) sodium dodecyl sulfate (SDS) polyacrylamide gels, and the electrophoresis was conducted for 2 h. After blocking free binding sites as described, primary antibodies against phosphorylated PERK, eIF2α, and IRE1α, and ERO1α, BIP/GRP78, GRP94, and nitrated proteins) sodium dodecyl sulfate (SDS) polyacrylamide gels, and the electrophoresis was conducted for 2 h. After blocking free binding sites as described, primary antibodies against phosphorylated PERK, eIF2α, and IRE1α, and ERO1α, BIP/GRP78, GRP94, and nitrated proteins) sodium dodecyl sulfate (SDS) polyacrylamide gels, and the electrophoresis was conducted for 2 h. After blocking free binding sites as described, primary antibodies against phosphorylated PERK, eIF2α, and IRE1α, and ERO1α, BIP/GRP78, GRP94, and nitrated proteins) sodium dodecyl sulfate (SDS) polyacrylamide gels, and the electrophoresis was conducted for 2 h. After blocking free binding sites as described, primary antibodies against phosphorylated PERK, eIF2α, and IRE1α, and ERO1α, BIP/GRP78, GRP94, and nitrated proteins) sodium dodecyl sulfate (SDS) polyacrylamide gels, and the electrophoresis was conducted for 2 h.
FIG. 1. Representative Western blot analyses of total and phosphorylated PERK (A), total and phosphorylated eIF2α (C), total and phosphorylated IRE1α (E), CHOP (G), GRP78/BiP (J), GRP94 (K), and ERO1α (M), and their contents (densitometry; B, D, F, H, J, L, and N) and, when applicable, phosphorylation states, in sciatic nerve of nondiabetic and diabetic rats maintained with or without trimethylamine oxide treatment for 12 weeks after induction of STZ diabetes (a prevention study). C, control; D, diabetic; TMAO, trimethylamine oxide. Mean ± SEM, n = 6–12 per group. *P < 0.05 and **P < 0.01 vs. nondiabetic controls; †P < 0.05 and ‡P < 0.01 vs. diabetic rats maintained without trimethylamine oxide treatment.
ELISA measurements of 4-HNE adducts and nitrotyrosine in rat sciatic nerve and spinal cord. For 4-HNE adduct measurements, the samples were homogenized in 20 mmol/L PBS, pH 7.4 (1:10 wt/vol), on ice. Homogenates were centrifuged at 14,000g (4°C, 20 min). Supernatants were used for measurements of 4-HNE adducts with the Oxiselect HNE-His Adduct ELISA kit (Cell BioLabs, San Diego, CA). For NT measurements, the samples were homogenized on ice in RIPA buffer (1:10 wt/vol) containing 50 mmol/L Tris-HCl, pH 7.2; 150 mmol/L NaCl; 0.1% sodium dodecyl sulfate; 1% NP-40; 5 mmol/L EDTA; 1 mmol/L EGTA; 1% sodium deoxycholate; and containing the protease/phosphatase inhibitors leupeptin (10 μg/mL); aprotonin (20 μg/mL); benzamidine (10 mmol/L); phenylmethylsulfonyl fluoride (1 mmol/L); and sodium orthovanadate (1 mmol/L). Homogenates were sonicated (3 x 5 s) and centrifuged at 14,000g (4°C, 20 min). Supernatants were used for measurements of NT concentrations with the Oxiselect Nitrotyrosine ELISA kit (Cell Bioslabs). 4-HNE adducts and NT concentrations were normalized per milligram of protein. Protein was measured with the bicinchoninic acid protein assay (Pierce Biotechnology, Rockford, IL).

Statistical analysis. The results are expressed as mean ± standard errors. The data were subjected to equality of variance F test, and then to log transformation, if necessary, before one-way ANOVA. The data were analyzed by the nonparametric Kruskal-Wallis one-way ANOVA, followed by the Bonferroni-Dunn or Fisher protected least significance (P) in spinal cord of nondiabetic and diabetic rats maintained with or without trimethylamine oxide treatment for 12 weeks after induction of STZ diabetes (a prevention study). C, control; D, diabetic. Mean ± SEM, n = 8–12 per group. *P < 0.05 and **P < 0.01 vs. nondiabetic controls; #P < 0.05 and ##P < 0.01 vs. diabetic rats maintained without trimethylamine oxide treatment.

RESULTS

Experiment 1. Experiment 1 involved ER stress and activation of UPR in neural tissues of STZ diabetic rats and their prevention by TMAO and PBA. Rats with 12-week duration of STZ diabetes displayed upregulation of UPR indicative of ER stress in sciatic nerve (Fig. 1) and spinal cord (Fig. 2). Sciatic nerve phospho-PERK level and phospho-PERK:total PERK ratio were increased by 32% and 37% (Fig. 1A, B). Phospho-eIF2α was increased by 27% (Fig. 1C, D). The diabetic condition was associated with a 31% increase in phospho-IRE1α:total IRE1α ratio (Fig. 1E, F).

Increased phospho-IRE1α:total IRE-1α ratio is consistent with increased levels of CHOP (Fig. 1G, H), the molecular chaperones BiP (Fig. 1I, J), and GRP94 (Fig. 1K, L), as well as CHOP-inducible ERO1α (Fig. 1M, N) by 18%, 41%, 19%, and 22%, respectively. TMAO, a chemical chaperone, blunted diabetes-induced activation of UPR, indicative of prevention of ER stress in peripheral nerve. In the spinal cord, the diabetic condition was associated with 42% and 20% increase in CHOP and ERO1α levels (Fig. 2A–D), whereas BiP (Fig. 2E, F), and GRP94 (Fig. 2G, H) levels were indistinguishable between control and diabetic rats. TMAO-treated diabetic rats preserved normal CHOP and ERO1α levels consistent with prevention of ER stress.

The effects of PBA on sciatic nerve phospho-eIF2α (Supplementary Fig. 1A), ERO1α (Supplementary Fig. 1B), CHOP (Supplementary Fig. 1C), and BiP/GRP78 (Fig. 1D) closely mimicked those of TMAO, consistent with the prevention of ER stress and activation of UPR by both chemical chaperones.

Chemical chaperones did not reduce diabetic hyperglycemia but attenuated DPN. Blood glucose concentrations were increased by 31%, 27%, and 31% in untreated and TMAO-treated and PBA-treated diabetic rats, respectively, compared with nondiabetic controls (Table 1). Rats with 12-week duration of STZ diabetes had development of MNCV (26%) and SNCV (13%) deficits (Table 2). They also displayed small sensory fiber neuropathy manifested in thermal and mechanical hypoalgesia as well as tactile allodynia, i.e., a condition when the light touch is perceived as painful. TMAO-treated and PBA-treated diabetic rats preserved normal SNCV and displayed less severe MNCV deficit and small sensory nerve fiber dysfunction than the untreated diabetic group. Diabetic rats exhibited 34% intraepidermal nerve fiber loss (Fig. 3A–D), which was attenuated, but not completely prevented, by TMAO.

**FIG. 2.** Representative Western blot analyses of CHOP (A), ERO1α (C), GRP78/BiP (F), and GRP94 (G), and their content (densitometry; B, D, F, and H) in spinal cord of nondiabetic and diabetic rats maintained with or without trimethylamine oxide treatment for 12 weeks after induction of STZ diabetes (a prevention study). C, control; D, diabetic. Mean ± SEM, n = 8–12 per group. *P < 0.05 and **P < 0.01 vs. nondiabetic controls; #P < 0.05 and ##P < 0.01 vs. diabetic rats maintained without trimethylamine oxide treatment.
Inhibition of ER stress attenuated oxidative-nitrative stress in the sciatic nerve and spinal cord of TMAO-treated rats. Rats with 12-week duration of STZ diabetes displayed oxidative-nitrative stress manifest by accumulation of 4-HNE adducts (66% and 42%) and nitrotyrosine (97% and 44%) in sciatic nerve (Fig. 3, E, F) and spinal cord (Fig. 3G, H). TMAO treatment attenuated oxidative-nitrative stress in both tissue targets for DPN.

**Experiment 2.** CHOP gene deficiency reduced the severities of diabetes-associated oxidative-nitrative stress in the sciatic nerve, as well as MNCV and SNCV deficits, thermal hypoalgesia, and intraepidermal nerve fiber loss. Nonfasting blood glucose concentrations were increased by 235% and by 190% in diabetic wild-type and diabetic CHOP^−/−^ mice, respectively (Table 3). Nondiabetic CHOP^−/−^ mice displayed normal MNCV, SNCV, thermal algesia, and tactile sensitivity, and had slightly increased mechanical withdrawal thresholds and INFD (Table 4, Fig. 4A, B). The wild-type mice with 12-week duration of STZ diabetes exhibited 220% increase in the sciatic nerve CHOP level (Fig. 4C, D), MNCV and SNCV deficits, increased thermal response latencies and mechanical withdrawal thresholds, and reduced tactile response thresholds and INFD. CHOP^−/−^ mice did not manifest any expression of CHOP in the sciatic nerve. CHOP gene deficiency reduced the severities of diabetes-associated oxidative-nitrative stress in the sciatic nerve, MNCV and SNCV deficits, thermal hypoalgesia, and intraepidermal nerve fiber loss, but did not have any beneficial effect on mechanical or tactile sensation.

**DISCUSSION**

The findings reported herein implicate ER stress, manifested in upregulation of UPR, in the development of DPN. In particular, ER stress leads to MNCV and SNCV deficits, small sensory nerve fiber dysfunction and degeneration, and oxidative-nitrative stress in peripheral nerve.

In the large-scale Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications study (32), improved blood glucose control reduced the risk of DPN associated with type 1 diabetes, thereby implicating hyperglycemia as a causative factor. Because severity of DPN strongly depends on blood glucose control, STZ diabetic rats exhibiting β-cell necrosis and irreversible hyperglycemia 2–3 days after induction of STZ comprise a suitable model for exploration of new pathogenetic mechanisms of DPN and drug discovery. Previous studies in STZ diabetic rats identified multiple pathogenetic mechanisms of DPN (6–9,13–15). The present findings demonstrating prevention of ER stress and attenuation of MNCV and SNCV deficits and small sensory nerve fiber dysfunction and degeneration, in the absence of alleviation of hyperglycemia, in chemical chaperone-treated STZ diabetic rats add ER stress to the list of pathogenetic mechanisms triggered either downstream of

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Group Variable</th>
<th>Nondiabetic</th>
<th>Nondiabetic + TMAO</th>
<th>Nondiabetic + PBA</th>
<th>Diabetic</th>
<th>Diabetic + TMAO</th>
<th>Diabetic + PBA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before induction of diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>281 ± 5</td>
<td>281 ± 5</td>
<td>281 ± 5</td>
<td>295 ± 14†</td>
<td>287 ± 12†</td>
<td></td>
</tr>
<tr>
<td>Blood glucose (mmol/L)</td>
<td>6.1 ± 0.2</td>
<td>6.1 ± 0.2</td>
<td>6.1 ± 0.2</td>
<td>25 ± 0.9†</td>
<td>23 ± 0.5‡</td>
<td>25 ± 0.8‡</td>
</tr>
<tr>
<td>Final measurements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>498 ± 19</td>
<td>542 ± 12§</td>
<td>476 ± 15</td>
<td>295 ± 14†</td>
<td>255 ± 9†‡</td>
<td></td>
</tr>
<tr>
<td>Blood glucose (mmol/L)</td>
<td>6.0 ± 0.2</td>
<td>6.1 ± 0.1</td>
<td>6.4 ± 0.2</td>
<td>25 ± 0.9†</td>
<td>23 ± 0.5‡</td>
<td>25 ± 0.8‡</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM. n = 12–22 per group. *P < 0.05; †P < 0.01 vs nondiabetic controls; and ‡P < 0.05 vs diabetic rats maintained without TMAO or PBA treatments.

**TABLE 2**

<table>
<thead>
<tr>
<th>Group variable</th>
<th>Nondiabetic</th>
<th>Nondiabetic + TMAO</th>
<th>Nondiabetic + PBA</th>
<th>Diabetic</th>
<th>Diabetic + TMAO</th>
<th>Diabetic + PBA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before induction of diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNCV (ms⁻¹)</td>
<td>58.4 ± 1.3</td>
<td>57.5 ± 1.2</td>
<td>57.2 ± 1.3</td>
<td>44.1 ± 1.0*</td>
<td>48.3 ± 1.6†</td>
<td>49 ± 1.6‡</td>
</tr>
<tr>
<td>SNCV (ms⁻¹)</td>
<td>42.7 ± 0.8</td>
<td>42.7 ± 0.8</td>
<td>42.7 ± 0.8</td>
<td>37.8 ± 0.9*</td>
<td>42.7 ± 1.2‡</td>
<td>44.3 ± 1.2‡</td>
</tr>
<tr>
<td>Thermal response latency (s)</td>
<td>8.6 ± 0.4</td>
<td>8.6 ± 0.4</td>
<td>8.6 ± 0.4</td>
<td>10.9 ± 0.3</td>
<td>22.8 ± 1.8*</td>
<td>18.2 ± 0.6‡</td>
</tr>
<tr>
<td>Mechanical withdrawal thresholds (g)</td>
<td>99 ± 3</td>
<td>112 ± 5</td>
<td>112 ± 5</td>
<td>156 ± 4*</td>
<td>133 ± 4‡</td>
<td>130 ± 5‡</td>
</tr>
<tr>
<td>Tactile response thresholds (g)</td>
<td>21.0 ± 1.4</td>
<td>18.4 ± 1.4</td>
<td>18.4 ± 1.4</td>
<td>7.6 ± 0.6*</td>
<td>14 ± 2*</td>
<td>14.3 ± 2.1‡</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM. n = 12–22 per group. *P < 0.01 vs. nondiabetic controls; †P < 0.05 and ‡P < 0.01 vs diabetic rats maintained without TMAO or PBA treatments.
hyperglycemia or by other factors in the diabetic milieu such as nonesterified fatty acids (33) or altered tissue lipid composition (34). This conclusion is supported by our data in STZ diabetic CHOP^22^ mice that displayed reduced severity of DPN, but not of the systemic hyperglycemia. Many clinical neuropathy trials failed because of a lack of robust end points sensitive to pharmacological interventions (35). Reduction in INFD is emerging as a sensitive marker of diabetes-induced small sensory nerve fiber degeneration from both clinical (36–38) and experimental (14,16–18,39) studies, but the biochemical mechanisms underlying this phenomenon are not well-understood. The present findings of attenuation of diabetes-induced intraepidermal nerve fiber loss by TMAO treatment or CHOP gene deficiency identify ER stress as an important contributor to small sensory nerve fiber loss in DPN.

Dissection of the contribution of long-term upregulation of the individual components of UPR to pathological conditions including diabetes and its complications is quite challenging because of the lack of specific inhibitors suitable for in vivo administration. Female CHOP^22^ mice on C57Bl6/J background preserved normal glucose tolerance and insulin sensitivity despite marked obesity (28). CHOP deletion in insulin-resistant mice profoundly increased

### TABLE 3

<table>
<thead>
<tr>
<th>Group variable</th>
<th>Nondiabetic wild-type</th>
<th>Nondiabetic CHOP^22^</th>
<th>Diabetic wild-type</th>
<th>Diabetic CHOP^22^</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before induction of diabetes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>24.2 ± 0.6</td>
<td>23.0 ± 0.7</td>
<td>6.7 ± 0.2</td>
<td></td>
</tr>
<tr>
<td>Blood glucose (mmol/L)</td>
<td>6.5 ± 0.2</td>
<td>6.7 ± 0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Final measurements</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>37.3 ± 0.7</td>
<td>40.1 ± 1.8*</td>
<td>29.2 ± 0.3†</td>
<td>27.5 ± 0.6†</td>
</tr>
<tr>
<td>Blood glucose (mmol/L)</td>
<td>7.2 ± 0.2</td>
<td>7.1 ± 1.6†</td>
<td>24.1 ± 1.6†</td>
<td>20.5 ± 1.3†‡</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM. *n = 9 – 20 per group. *P < 0.05 and †P < 0.01 vs. corresponding nondiabetic controls; ‡P < 0.05 vs. diabetic wild-type mice.

---

FIG. 3. Representative images of intraepidermal nerve fiber profiles (4A) magnification ×400, intraepidermal nerve fiber densities (B), and indices of oxidative-nitrative stress in sciatic nerve and spinal cord (C–F) in nondiabetic and diabetic rats maintained with or without trimethylamine oxide treatment for 12 weeks after induction of STZ diabetes (a prevention study). C, control; D, diabetic; INFD, intraepidermal nerve fiber density. Mean ± SEM, *n = 8–12 per group. *P < 0.05 and **P < 0.01 vs. nondiabetic controls; †P < 0.05 and ‡P < 0.01 vs. diabetic rats maintained without trimethylamine oxide treatment.
TABLE 4
Variables of peripheral nerve function in nondiabetic and diabetic CHOP-deficient mice

<table>
<thead>
<tr>
<th>Group variable</th>
<th>Nondiabetic wild-type</th>
<th>Nondiabetic CHOP−/−</th>
<th>Diabetic wild-type</th>
<th>Diabetic CHOP−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before induction of diabetes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNCV (ms⁻¹)</td>
<td>51.6 ± 1.3</td>
<td>50.9 ± 1.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNCV (ms⁻¹)</td>
<td>39.8 ± 0.6</td>
<td>39.6 ± 0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thermal response latency (s)</td>
<td>8.7 ± 0.2</td>
<td>8.4 ± 0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical withdrawal thresholds (g)</td>
<td>110 ± 3</td>
<td>113 ± 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tactile response thresholds (g)</td>
<td>1.93 ± 0.21</td>
<td>1.87 ± 0.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Final measurements</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNCV (ms⁻¹)</td>
<td>52.2 ± 1.7</td>
<td>51.2 ± 1.1</td>
<td>43.8 ± 2.1*</td>
<td>48.9 ± 1.1†</td>
</tr>
<tr>
<td>SNCV (ms⁻¹)</td>
<td>40.8 ± 0.7</td>
<td>39.9 ± 0.6</td>
<td>32.8 ± 1.1*</td>
<td>39.4 ± 0.5‡</td>
</tr>
<tr>
<td>Thermal response latency (s)</td>
<td>9.3 ± 0.3</td>
<td>10.4 ± 0.2</td>
<td>16.8 ± 0.9*</td>
<td>13.1 ± 0.2‡</td>
</tr>
<tr>
<td>Mechanical withdrawal thresholds (g)</td>
<td>116 ± 2</td>
<td>126 ± 2</td>
<td>146 ± 4*</td>
<td>150 ± 2*</td>
</tr>
<tr>
<td>Tactile response thresholds (g)</td>
<td>1.88 ± 0.18</td>
<td>1.66 ± 0.10</td>
<td>0.89 ± 0.05*</td>
<td>0.85 ± 0.04*</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM. n = 9–20 per group. *P < 0.01 vs. corresponding nondiabetic controls; †P < 0.05 and ‡P < 0.01 vs. diabetic wild-type mice.

pancreatic β-cell mass and their ability to forestall the progression of diabetes (40,41). Aged STZ diabetic CHOP−/− mice did not have development of renal mesangial expansion and albuminuria (29). Our findings of diabetes-associated increase in peripheral nerve CHOP level in wild-type mice and of reduced severity of MNCV and SNCV deficits, thermal hypogalgesia, and intraepidermal nerve fiber degeneration in STZ diabetic CHOP−/− mice implicate CHOP in DPN.

It is well-established that intracellular oxidative-nitrative stress induces ER stress (42–44). In contrast, the role of ER stress in the development of oxidative-nitrative stress and, in particular, in diabetes is not understood properly. Under normal conditions, generation of ~25% of reactive oxygen species in mammalian cells is a consequence of formation of disulfide bonds in the ER during oxidative protein folding (41,44). In this process, ER oxidoreductases, including protein disulphide isomerase (PDI), catalyze formation, isomerization, and reduction of disulfide bonds. During disulfide bond formation, cysteine residues within the PDI active site accept two electrons from thiol residues in the polypeptide chain substrate. Reduced PDI transfers its electrons through ERO1a to molecular oxygen as the final electron acceptor (41,44). Hydrogen peroxide is formed as a byproduct from the sequential action of PDI and ERO1a.

Upregulation of PDI and ERO1a under conditions of ER stress therefore should result in excessive hydrogen peroxide formation. Hydrogen peroxide neutralization may be impaired because of glutathione depletion that occurs in the process of glutathione oxidation during reduction of disulfide bonds. ER causes induction of NAD(P)H oxidase-2 and NAD(P)H oxidase-dependent oxidative stress via CHOP and ERO1α-mediated release of ER Ca++ (45). ERO1α-mediated release of ER Ca++ at the mitochondria-associated membrane, with concomitant mitochondrial fission and Ca++ overload, also may lead to increased mitochondrial superoxide generation (46–48). Whereas CHOP overexpression has been reported to perturb the cellular redox state (49) and to increase superoxide generation (50), CHOP gene deficiency induced expression of the genes encoding antioxidant response and reduced protein carbonyl and hydroxyoctadecadienoic acid production (40). Attenuation of 4-HNE adducts and NT accumulation in peripheral nerve and spinal cord of TMAO-treated diabetic rats in the current study suggest that ER stress provides an important contribution to oxidative-nitrative stress in the peripheral nervous system.
system in diabetes. This observation consistent with less pronounced nitrated protein accumulation in diabetic CHOP−/− mice is highly significant because oxidative-nitratere stress is one of the key mechanisms underlying MNCV and SNCV deficits, neurovascular dysfunction, and small sensor fiber neuropathy in diabetes (6–9,12,15,39).

In conclusion, our findings demonstrate an important contribution of ER stress completely and of the specific component of UPR, CHOP, to both large and small fiber neuropathies, and identify new therapeutic direction for this devastating complication of diabetes mellitus. With consideration of a key role of reduced nerve blood flow and endoneurial hypoxia in diabetes-induced MNCV and SNCV deficits (6–8,13), and of involvement of ER stress in other diabetic microvascular complications, such as nephropathy (29) and retinopathy (30), future studies should dissect the role for ER stress/UPR in neurovascular dysfunction associated with diabetes. Interactions among ER stress and other biochemical mechanisms implicated in the pathogenesis of DPN also need to be explored. In addition, our work provides rationale for evaluation of variables of ER stress in easily accessible biological materials (peripheral blood monocytes, skin) as potential biomarkers of DPN with diagnostic and prognostic value.

ACKNOWLEDGMENTS
S.L., P.W., R.S., H.S., and I.G.O. were partially supported by the National Institutes of Health Grants RO1-DK-074517, RO1-DK-077141, and RO1-DK-081147, and American Diabetes Association Research Grant 7-08-RA-102 (all to I.G.O.). The Cell Biology and Bioimaging Core utilized in this work is supported in part by COBRE (NIH P20 RR0-21945) and CNRU (NIH 1P30-DK-072476) center grants from the National Institutes of Health.

No potential conflicts of interest relevant to this article were reported.

S.L. performed most of Western blot analyses and participated in MNCV and SNCV measurements. P.W. was responsible for animal treatment, CHOP−/− mouse colony development and maintenance, and behavioral tests. R.S. performed the remaining part of Western blot analyses as well as ELISA assays. H.S. performed assessment of intraepidermal nerve fiber density. All authors participated in the data discussion. I.G.O. wrote the manuscript. H.S. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Dr. Douglas E. Wright from the University of Kansas Medical Center, Kansas City, Kansas, for valuable recommendations regarding intraepidermal nerve fiber density measurements.

NOTE ADDED IN PROOF
The authors are deeply saddened by the loss of dear colleague and mentor, Dr. Irina Obrosova. Dr. Obrosova died on December 4, 2012. She continued to work until the very last moment despite her difficult fight with a terminal disease. Her selfless devotion and invaluable contribution to the field of diabetic complications will be remembered by everyone who knew her.

REFERENCES
8. Cameron NE, Tuck Z, McCabe L, Cotter MA. Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 2001;44:1161–1169
41. Kaufman RJ, Back SH, Song B, Han J, Hassler J. The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in β-cells. Diabetes Obes Metab 2010;12(Suppl 2):99–107
48. Yu T, Jhun BS, Yoon Y. High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid Redox Signal 2011;14:425–437